percutaneous coronary intervention
Matrizyme Completes Phase I Program
March 16th, 2012
Toronto, Ontario (PRWEB) January 26, 2012 Matrizyme Pharma Corporation (Matrizyme) today announced the completion of its phase I clinical program for its lead product, MZ-004, for the treatment of coronary … Read more